Efficacies of KY62 against Leishmania amazonensis and Leishmania donovani in experimental murine cutaneous leishmaniasis and visceral leishmaniasis

Hail M. Al-Abdely, John R. Graybill, Rosie Bocanegra, Laura Najvar, Eleanor Montalbo, Steven L. Regen, Peter Melby

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Current therapy for leishmaniasis is unsatisfactory because parenteral antimonial salts and pentamidine are associated with significant toxicity and failure rates. We examined the efficacy of KY62, a new, water-soluble, polyene antifungal, against cutaneous infection with Leishmania amazonensis and against visceral infection with Leishmania donovani in susceptible BALB/c mice. Mice were infected with L. amazonensis promastigotes in the ear pinna and in the tail and were treated with KY62 or amphotericin B. The cutaneous lesions showed a remarkable response to therapy with KY62 at a dose of 30 mg per kg of body weight per day. At this dose, the efficacy of KY62 was equivalent to or better than that of amphotericin B at 1 to 5 mg/kg/day. Mice infected intravenously with 107 L. donovani promastigotes and treated with KY62 showed a 4-log reduction in the parasite burden in the liver and spleen compared to untreated mice. These studies indicate potent activity of KY62 against experimental cutaneous leishmaniasis caused by L. amazoniensis and against experimental visceral leishmaniasis caused by L. donovani.

Original languageEnglish (US)
Pages (from-to)2542-2548
Number of pages7
JournalAntimicrobial Agents and Chemotherapy
Volume42
Issue number10
StatePublished - Oct 1998
Externally publishedYes

Fingerprint

Leishmania donovani
Cutaneous Leishmaniasis
Visceral Leishmaniasis
Amphotericin B
Ear Auricle
Pentamidine
Polyenes
Skin
Leishmaniasis
Leishmania
Infection
Tail
Parasites
Spleen
Salts
Body Weight
Water
Liver
Therapeutics

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Efficacies of KY62 against Leishmania amazonensis and Leishmania donovani in experimental murine cutaneous leishmaniasis and visceral leishmaniasis. / Al-Abdely, Hail M.; Graybill, John R.; Bocanegra, Rosie; Najvar, Laura; Montalbo, Eleanor; Regen, Steven L.; Melby, Peter.

In: Antimicrobial Agents and Chemotherapy, Vol. 42, No. 10, 10.1998, p. 2542-2548.

Research output: Contribution to journalArticle

Al-Abdely, Hail M. ; Graybill, John R. ; Bocanegra, Rosie ; Najvar, Laura ; Montalbo, Eleanor ; Regen, Steven L. ; Melby, Peter. / Efficacies of KY62 against Leishmania amazonensis and Leishmania donovani in experimental murine cutaneous leishmaniasis and visceral leishmaniasis. In: Antimicrobial Agents and Chemotherapy. 1998 ; Vol. 42, No. 10. pp. 2542-2548.
@article{d3ffd227cf8a4ce6bec30ff554cc09ef,
title = "Efficacies of KY62 against Leishmania amazonensis and Leishmania donovani in experimental murine cutaneous leishmaniasis and visceral leishmaniasis",
abstract = "Current therapy for leishmaniasis is unsatisfactory because parenteral antimonial salts and pentamidine are associated with significant toxicity and failure rates. We examined the efficacy of KY62, a new, water-soluble, polyene antifungal, against cutaneous infection with Leishmania amazonensis and against visceral infection with Leishmania donovani in susceptible BALB/c mice. Mice were infected with L. amazonensis promastigotes in the ear pinna and in the tail and were treated with KY62 or amphotericin B. The cutaneous lesions showed a remarkable response to therapy with KY62 at a dose of 30 mg per kg of body weight per day. At this dose, the efficacy of KY62 was equivalent to or better than that of amphotericin B at 1 to 5 mg/kg/day. Mice infected intravenously with 107 L. donovani promastigotes and treated with KY62 showed a 4-log reduction in the parasite burden in the liver and spleen compared to untreated mice. These studies indicate potent activity of KY62 against experimental cutaneous leishmaniasis caused by L. amazoniensis and against experimental visceral leishmaniasis caused by L. donovani.",
author = "Al-Abdely, {Hail M.} and Graybill, {John R.} and Rosie Bocanegra and Laura Najvar and Eleanor Montalbo and Regen, {Steven L.} and Peter Melby",
year = "1998",
month = "10",
language = "English (US)",
volume = "42",
pages = "2542--2548",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "10",

}

TY - JOUR

T1 - Efficacies of KY62 against Leishmania amazonensis and Leishmania donovani in experimental murine cutaneous leishmaniasis and visceral leishmaniasis

AU - Al-Abdely, Hail M.

AU - Graybill, John R.

AU - Bocanegra, Rosie

AU - Najvar, Laura

AU - Montalbo, Eleanor

AU - Regen, Steven L.

AU - Melby, Peter

PY - 1998/10

Y1 - 1998/10

N2 - Current therapy for leishmaniasis is unsatisfactory because parenteral antimonial salts and pentamidine are associated with significant toxicity and failure rates. We examined the efficacy of KY62, a new, water-soluble, polyene antifungal, against cutaneous infection with Leishmania amazonensis and against visceral infection with Leishmania donovani in susceptible BALB/c mice. Mice were infected with L. amazonensis promastigotes in the ear pinna and in the tail and were treated with KY62 or amphotericin B. The cutaneous lesions showed a remarkable response to therapy with KY62 at a dose of 30 mg per kg of body weight per day. At this dose, the efficacy of KY62 was equivalent to or better than that of amphotericin B at 1 to 5 mg/kg/day. Mice infected intravenously with 107 L. donovani promastigotes and treated with KY62 showed a 4-log reduction in the parasite burden in the liver and spleen compared to untreated mice. These studies indicate potent activity of KY62 against experimental cutaneous leishmaniasis caused by L. amazoniensis and against experimental visceral leishmaniasis caused by L. donovani.

AB - Current therapy for leishmaniasis is unsatisfactory because parenteral antimonial salts and pentamidine are associated with significant toxicity and failure rates. We examined the efficacy of KY62, a new, water-soluble, polyene antifungal, against cutaneous infection with Leishmania amazonensis and against visceral infection with Leishmania donovani in susceptible BALB/c mice. Mice were infected with L. amazonensis promastigotes in the ear pinna and in the tail and were treated with KY62 or amphotericin B. The cutaneous lesions showed a remarkable response to therapy with KY62 at a dose of 30 mg per kg of body weight per day. At this dose, the efficacy of KY62 was equivalent to or better than that of amphotericin B at 1 to 5 mg/kg/day. Mice infected intravenously with 107 L. donovani promastigotes and treated with KY62 showed a 4-log reduction in the parasite burden in the liver and spleen compared to untreated mice. These studies indicate potent activity of KY62 against experimental cutaneous leishmaniasis caused by L. amazoniensis and against experimental visceral leishmaniasis caused by L. donovani.

UR - http://www.scopus.com/inward/record.url?scp=0031680682&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031680682&partnerID=8YFLogxK

M3 - Article

VL - 42

SP - 2542

EP - 2548

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 10

ER -